GSK ramps up Shingrix production with $100m investment

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/RaksyBH)
(Image: Getty/RaksyBH)

Related tags Gsk Shingrix Shingles

GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.

The $100m (€89.7m) investment will be spent on GSK’s manufacturing site in Montana, US, and will add production capacity of key components of the adjuvant system used in several of the company’s vaccines.

The 193,000-square-foot Hamilton site produces monophosphoryl lipid, a bacterially-derived adjuvant, which is a component used in the creation of various vaccines GSK holds in its portfolio, including Shingrix, a recombinant zoster vaccine.

In addition to expanding the facility’s capacity, the company expects the investment will add to the current 200 employees at the site with the addition of jobs in R&D and manufacturing.

GSK’s has previously explained that demand for its Shingrix vaccine in 2018 outstripped supply​, as a result, it has had to limit orders and expects this position to continue for the rest of 2019.

With the increased investment in the facility, the company expects to be able to make its supply more robust.

Jack Bailey, president of US Pharmaceuticals at GSK, said, “By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix.”

In full-year 2018 results, GSK revealed that the Shingrix vaccine had sales of £784m ($1bn), amid a US market that saw rapid uptake of the vaccine – a spokesperson previously told us that more vaccines were delivered in the first half of 2018 than the entire year of 2017.

The full expansion project will take two to three years to complete, while the specific upgrade at its Hamilton site will take place “over the next few years​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more